According to a recent LinkedIn post from Orasis Pharmaceuticals, the company is planning a visible presence at the SECO 2026 optometry meeting, including activities at Booth #133. The post highlights a breakfast symposium aimed at addressing what it describes as myths around pilocarpine, led by several optometrists with FAAO credentials.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also points to a scientific poster session focused on concentration‑dependent effects of low‑concentration pilocarpine, suggesting continued interest in clinical and mechanistic data around this compound. For investors, this emphasis on professional education and scientific engagement may signal ongoing efforts to strengthen clinical positioning and prescriber awareness, which could be relevant to future market adoption and competitive differentiation in the vision‑care segment.